Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Deep Intelligent Pharma Raises $15 Million for AI Drug Development from Sequoia

publication date: Oct 9, 2018

Deep Intelligent Pharma, a Beijing healthcare AI startup, raised $15 million in a Series B round from Sequoia Capital China. DIP has assembled a team that combines AI engineers with experts in drug R&D to accelerate drug discovery, development and medical affairs using advanced AI and blockchain technologies. In May, DIP completed a $6.6 million series A round from Zhen Fund, which also invested in the 2017 Pre-A funding. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Other Events

www.chinatrialsevent.com

Shanghai,China

November 7–9, 2018

ChinaBio members can get a 20% discount with the promotion code"chinabio18"